CITADEL ADVISORS LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:24 pm Sale | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | CITADEL ADVISORS LLC | 1,734,094 3.700% | -660,354 (-27.58%) | Filing |
| 2024-02-14 6:18 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | CITADEL ADVISORS LLC | 426,857 0.600% | 426,857 (New Position) | Filing |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | CITADEL ADVISORS LLC | 2,394,448 5.800% | 95,692 (+4.16%) | Filing |
| 2023-03-06 4:11 pm Purchase | 2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN | CITADEL ADVISORS LLC | 2,298,756 5.600% | 2,298,756 (New Position) | Filing |